AU2020252050A1 - Lipocalin mutein for treatment of asthma - Google Patents

Lipocalin mutein for treatment of asthma Download PDF

Info

Publication number
AU2020252050A1
AU2020252050A1 AU2020252050A AU2020252050A AU2020252050A1 AU 2020252050 A1 AU2020252050 A1 AU 2020252050A1 AU 2020252050 A AU2020252050 A AU 2020252050A AU 2020252050 A AU2020252050 A AU 2020252050A AU 2020252050 A1 AU2020252050 A1 AU 2020252050A1
Authority
AU
Australia
Prior art keywords
fragment
variant
lipocalin mutein
subject
delivered dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020252050A
Other languages
English (en)
Inventor
Lena Therese AXELSSON
Ingmar BRUNS
David Robert Close
Mary Fitzgerald
Philip Gardiner
Aulikki Ingergard Alexandra JAUHIANINEN
Gabriele Matschiner
Gunnel Marita OLSSON
Ekaterina PARDALI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2020252050A1 publication Critical patent/AU2020252050A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
AU2020252050A 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma Abandoned AU2020252050A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962826791P 2019-03-29 2019-03-29
US62/826,791 2019-03-29
US201962845774P 2019-05-09 2019-05-09
US62/845,774 2019-05-09
US201962906443P 2019-09-26 2019-09-26
US62/906,443 2019-09-26
PCT/EP2020/058360 WO2020200960A1 (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Publications (1)

Publication Number Publication Date
AU2020252050A1 true AU2020252050A1 (en) 2021-11-11

Family

ID=70008540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020252050A Abandoned AU2020252050A1 (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Country Status (11)

Country Link
US (1) US20220193191A1 (https=)
EP (1) EP3946415A1 (https=)
JP (1) JP2022526524A (https=)
KR (1) KR20210146934A (https=)
CN (1) CN113613669A (https=)
AU (1) AU2020252050A1 (https=)
CA (1) CA3133422A1 (https=)
IL (1) IL286756A (https=)
MA (1) MA55490A (https=)
SG (1) SG11202109839YA (https=)
WO (1) WO2020200960A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
KR20230121785A (ko) 2020-12-18 2023-08-21 아스트라제네카 에이비이 천식 치료용 리포칼린 뮤테인 건조 분말 제형
WO2023143351A1 (zh) 2022-01-29 2023-08-03 上海盛迪医药有限公司 糖皮质激素的药物偶联物
CN114780621B (zh) * 2022-06-23 2022-10-04 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法
WO2025026216A1 (zh) 2023-07-28 2025-02-06 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
RU2569745C2 (ru) * 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
ES2710384T3 (es) * 2011-12-13 2019-04-24 Pieris Pharmaceuticals Gmbh Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores

Also Published As

Publication number Publication date
EP3946415A1 (en) 2022-02-09
IL286756A (en) 2021-10-31
JP2022526524A (ja) 2022-05-25
WO2020200960A1 (en) 2020-10-08
SG11202109839YA (en) 2021-10-28
CN113613669A (zh) 2021-11-05
US20220193191A1 (en) 2022-06-23
MA55490A (fr) 2022-02-09
KR20210146934A (ko) 2021-12-06
CA3133422A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US20220193191A1 (en) Lipocalin mutein for treatment of asthma
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
EP2627673B1 (en) Therapies for improving pulmonary function
US20070122351A1 (en) Inhalation Drug Combinations
US8410049B2 (en) Methods and kits for preventing hypoglycemia
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
Voshaar et al. A randomized study of tiotropium Respimat® Soft MistTM Inhaler vs. ipratropium pMDI in COPD
KR102337599B1 (ko) 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
US20060013775A1 (en) Use of ppar activators for the treatment of pulmonary fibrosis
Tashkin et al. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD
ZuWallack et al. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI
CA3199479A1 (en) Lipocalin mutein dry powder formulation for treatment of asthma
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
Mason American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019
US20100063251A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
CN116249545A (zh) 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化
Petraitytė Utilization and costs of drugs for asthma and chronic obstructive pulmonary disease treatment in Lithuania on 2006-2009 year
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function
HK1240824A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period